home / stock / hrtx / hrtx news

HRTX News and Press, Heron Therapeutics Inc. From 02/20/19

Stock Information
Company Name: Heron Therapeutics Inc.
Stock Symbol: HRTX
Market: NASDAQ
Website: herontx.com
Menu
HRTX HRTX Quote HRTX Short HRTX News HRTX Articles HRTX Message Board
Get HRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
HRTX - Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference

SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barr...
HRTX - Biotech Bonanza: The Mergers And Acquisitions Theme

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

HRTX - Heron Therapeutics Announces Retirement of Robert Rosen as President

SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Rob...

HRTX - ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q4 2018

Editor’s Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

HRTX - Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics

NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged at 2.25% to 2.50%. The Dow Jones Industrial Average went higher by 1.77 percent to ...

HRTX - New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis - Consolidated Revenues, Company Growth, and Expectations for 2019

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star Bu...

HRTX - Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

SAN DIEGO , Jan. 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted pr...
HRTX - FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

SAN DIEGO , Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...

HRTX - Heron Therapeutics misses by $0.04, beats on revenue

Heron Therapeutics (NASDAQ: HRTX ): Q3 GAAP EPS of -$0.49 misses by $0.04 . More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

HRTX - Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial ...
Previous 10 Next 10